The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
CHEK2*1100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls
Abstract
Purpose: CHEK2*1100delC heterozygosity may be associated with an increased risk of breast cancer; however, it is unclear whether the evidence is sufficient to recommend genotyping in clinical practice. Patients and Methods: We identified studies on CHEK2*1100delC heterozygosity and the risk of unselected, early-onset, and familial breast cancer through comprehensive, computer-based searches of PubMed, EMBASE, and Web of Science. Aggregated risk estimates were compared with previous estimates for BRCA1 and BRCA2 mutation heterozygotes. Results: By using fixed-effect models for CHEK2*1100delC heterozygotes versus noncarriers, we found aggregated odds ratios of 2.7 (95% CI, 2.1 to 3.4) for unselected breast cancer, 2.6 (95% CI, 1.3 to 5.5) for early-onset breast cancer, and 4.8 (95% CI, 3.3 to 7.2) for familial breast cancer. For familial breast cancer, this corresponds to a cumulative risk of breast cancer at age 70 years in CHEK2*1100delC heterozygotes of 37% (95% CI, 26% to 56%), which compares with similar previous estimates of 57% (95% CI, 47% to 66%) for BRCA1 mutation heterozygotes and 49% (95% CI, 40% to 57%) for BRCA2 mutation heterozygotes. Conclusion: These meta-analyses emphasize that CHEK2*1100delC is an important breast cancer–predisposing gene, which increases the risk three- to five-fold. Because the cumulative risk of breast cancer at age 70 years among familial patient cases for CHEK2*1100delC heterozygotes is almost as high as that for BRCA1 and BRCA2 mutation heterozygotes, genotyping for CHEK2*1100delC should be considered together with BRCA1 and BRCA2 mutation screening in women with a family history of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802 · cited 6×
“We also compared these results with a recent metaanalysis on the risk of breast cancer for women with mutations in BRCA1 or BRCA2.”
MethodResultInfluentialChk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 904
CHEK2 Is a Multiorgan Cancer Susceptibility Gene
Cybulski, C., Górski, B., Huzarski, T., Masojć, B., Mierzejewski, M., Dębniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/426403 · Cited by 551
(2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 471
A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer
Vahteristo, P., Bartkova, J., Eerola, H., Syrjäkoski, K., Ojala, S., Kilpivaara, O., Tamminen, A., Kononen, J., Aittomäki, K., Heikkilä, P., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/341943 · Cited by 467
Meijers-Heijboer, H., Wasielewski, M., Wagner, A., Hollestelle, A., Elstrodt, F., van den Bos, R., de Snoo, A., Tjon A Fat, G., Brekelmans, C., Jagmohan, S., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375121 · Cited by 227
The CHEK2 gene and inherited breast cancer susceptibility
Nevanlinna, H., & Bartek, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209877 · Cited by 219
Family History, Age, and Risk of Breast Cancer: Prospective Data From the Nurses' Health Study
Colditz, G. A. (1993) · JAMA · doi:10.1001/jama.1993.03510030062035 · Cited by 211
Respiratory chain complex V deficiency due to a mutation in the assembly gene ATP12
De Meirleir, L., Seneca, S., Lissens, W., De Clercq, I., Eyskens, F., Gerlo, E., Smet, J., & Van Coster, R. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.012047 · Cited by 200
Increased Risk of Breast Cancer Associated With CHEK2*1100delC
Weischer, M., Bojesen, S. E., Tybjærg‐Hansen, A., Axelsson, C. K., & Nordestgaard, B. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5160 · Cited by 138
Self-citationFrequency of CHEK2*1100delC in New York breast cancer cases and controls
Offit, K., Pierce, H., Kirchhoff, T., Kolachana, P., Rapaport, B., Gregersen, P. K., Johnson, S., Yossepowitch, O., Huang, H. J., Satagopan, J. M., et al. (2003) · BMC Medical Genetics · doi:10.1186/1471-2350-4-1 · Cited by 137
Breast cancer predisposing alleles in Poland
Górski, B., Cybulski, C., Huzarski, T., Byrski, T., Gronwald, J., Jakubowska, A., Stawicka, M., Grodecka-Gazdecka, S., Szwiec, M., Urbański, K., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-1409-1 · Cited by 128
Schmidt, M. K., Tollenaar, R. A. �. �., Kemp, S. R. M., Broeks, A., Cornelisse, C. J., Smit, V. T. H. B. M., Peterse, J. L., van Leeuwen, F. E., & Veer, L. V. ‘. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3024 · Cited by 121
Kilpivaara, O., Bártková, J., Eerola, H., Syrjäkoski, K., Vahteristo, P., Lukas, J., BLOMQVIST, C. P., Holli, K., Heikkilä, P., Sauter, G., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20638 · Cited by 116
A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland
Cybulski, C., Wokołorczyk, D., Huzarski, T., Byrski, T., Gronwald, J., Górski, B., Dębniak, T., Masojć, B., Jakubowska, A., van de Wetering, T., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9320-y · Cited by 113
Limited relevance of the CHEK2 gene in hereditary breast cancer
Dufault, M. R., Betz, B., Wappenschmidt, B., Hofmann, W., Bandick, K., Golla, A., Pietschmann, A., Nestle-Krämling, C., Rhiem, K., Hüttner, C., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20073 · Cited by 94
Osório, A., Rodríguez‐López, R., Dı́ez, O., de la Hoya, M., Martínez, J. I., Vega, A. I., Esteban‐Cardeñosa, E., Alonso, C., Caldés, T., & Benitez, J. J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11414 · Cited by 81
Sodha, N., Bullock, S. L., Taylor, R., Mitchell, G., Guertl‐Lackner, B., Williams, R. D., Bevan, S., Bishop, K., McGuire, S., Houlston, R. S., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600637 · Cited by 72
CHEK2 1100delC is not a risk factor for male breast cancer population
Syrjäkoski, K., Kuukasjärvi, T., Auvinen, A. P., & Kallioniemi, O. (2003) · International Journal of Cancer · doi:10.1002/ijc.11384 · Cited by 63
A Multicenter Study of Cancer Incidence in CHEK2 1100delC Mutation Carriers
Thompson, D. J., Seal, S., Schutte, M. E. M., McGuffog, L., Barfoot, R., Renwick, A., Eeles, R. A., Sodha, N., Houlston, R. S., Shanley, S., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0687 · Cited by 61
Friedrichsen, D. M., Malone, K. E., Doody, D. R., Daling, J. R., & Ostrander, E. A. (2004) · Breast Cancer Research · doi:10.1186/bcr933 · Cited by 60
Bernstein, J. L., Teraoka, S. N., John, E. M., Andrulis, I. L., Knight, J. A., Lapinski, R. H., Olson, E. R., Wolitzer, A. L., Seminara, D., Whittemore, A. S., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0557 · Cited by 54
Role of CHEK2*1100delC in unselected series of non‐BRCA1/2 male breast cancers
Neuhausen, S. L., Dunning, A. M., Steele, L., Yakumo, K., Hoffman, M. D., Szabo, C., Tee, L. J., Baines, C., Pharoah, P. D. P., Goldgar, D. E., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11385 · Cited by 52
CHEK2*1100delC and male breast cancer risk in Israel
Ohayon, T., Gal, I., Baruch, R. G., Szabo, C., & Friedman, E. (2003) · International Journal of Cancer · doi:10.1002/ijc.11603 · Cited by 50
Rajkumar, T., Soumittra, N., Nancy, N. K., Swaminathan, R., Veluswami, S., & Shanta, V. (2003) · PubMed · Cited by 50
The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy
Caligo, M. A., Agata, S., Aceto, G. M., Crucianelli, R., Manoukian, S., Peissel, B., Scaini, M. C., Sensi, E., Veschi, S., Cama, A., et al. (2004) · Human Mutation · doi:10.1002/humu.20051 · Cited by 44
Linkage Disequilibrium Mapping of CHEK2: Common Variation and Breast Cancer Risk
Einarsdóttir, K., Humphreys, K., Bonnard, C., Palmgren, J., Iles, M. M., Sjölander, A., Li, Y., Chia, K. S., Liu, E. T., Hall, P. N., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030168 · Cited by 41
Rashid, M. U., Jakubowska, A., Justenhoven, C., Harth, V., Pesch, B., Baisch, C., Pierl, C. B., Brüning, T., Ko, Y. D., Benner, A., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.049 · Cited by 40
CHEK2 1100delC mutation is frequent among Russian breast cancer patients
Преображенская, Е. В., Соколенко, А. П., Buslov, K. G., Iyevleva, A. G., Ulibina, Y. M., Rozanov, M. E., Mitiushkina, N. V., Togo, A. V., Matsko, D. E., Voskresenskiy, D. A., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9227-7 · Cited by 40
CHEK2-Positive Breast Cancers in Young Polish Women
Cybulski, C., Górski, B., Huzarski, T., Byrski, T., Gronwald, J., Dębniak, T., Wokołorczyk, D., Jakubowska, A., Kowalska, E., Oszurek, O., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0158 · Cited by 39
CHEK2 1100delC is present in familial breast cancer cases of the Basque Country
Martínez-Bouzas, C., Beristain, E., Guerra, I., Gorostiaga, J. M., Mendizabal‐Zubiaga, J., De-Pablo, J.-L., García-Alegría, E., Sanz-Parra, A., & Tejada, M. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9351-4 · Cited by 29
CHEK2:1100delC and female breast cancer in the United States
Pereira, L. H. M., Sigurdson, A. J., Doody, M. M., Pineda, M. A., Alexander, B. H., Greene, M. H., & Struewing, J. P. (2004) · International Journal of Cancer · doi:10.1002/ijc.20439 · Cited by 21
Absence of CHEK2 mutations in Spanish families with hereditary breast cancer
Bellosillo, B., Tusquets, I., Longarón, R., Pérez-Lezaun, A., Bellet, M., Fabregat, X., Serrano, S., & Solé, F. G. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.01.016 · Cited by 19
de Jong, M. M., Nolte, I. M., Meerman, G. J. T., van der Graaf, W. T. A., Oosterom, E., Bruinenberg, M., van der Steege, G., Oosterwijk, J. C., van der Hout, A. H., Boezen, H. M., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.035 · Cited by 17
The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families
de Abajo, A. S., de la Hoya, M., Godino, J., Furió, V., Tosar, A., Pérez‐Segura, P., Díaz‐Rubio, E., & Caldés, T. (2005) · Familial Cancer · doi:10.1007/s10689-004-5813-1 · Cited by 16
Chromosomal radiosensitivity of breast cancer with a mutation
Baeyens, A., Claes, K., Willems, P. H. G. M., DERUYCK, K., Thierens, H. M., & Vral, A. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.04.017 · Cited by 15
Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers
Huang, J., Domchek, S. M., Brose, M. S., Rebbeck, T. R., Nathanson, K. L., & Weber, B. L. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.022913 · Cited by 15
Analysis of familial male breast cancer for germline mutations in CHEK2
Sodha, N., Wilson, C., Bullock, S. L., Phillimore, H., Houlston, R. S., & Eeles, R. A. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.07.002 · Cited by 13
Kleibl, Z., Novotný, J., Pohlreich, P., Zikán, M., Cinek, P., Janatová, M., & Petruzelka, L. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.9538 · Cited by 1
Cited by
Breast-Cancer Risk in Families with Mutations in PALB2
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 851
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 529
RetractedMalkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
Genetic Susceptibility to Cancer: The Role of Polymorphisms in Candidate Genes
Dong, L. M., Potter, J. D., White, E., Ulrich, C. M., Cardon, L. R., & Peters, U. (2008) · JAMA · doi:10.1001/jama.299.20.2423 · Cited by 461
Metadata
- Authors
- Weischer, M., Bojesen, S. E., Ellervik, C., Tybjærg-Hansen, A., & Nordestgaard, B. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-02-01
- Volume
- 26
- Issue
- 4
- Pages
- 542-548
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149805321
- Cited by
- 306
- References
- 42
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.